Hepcidin and HFE protein: Iron metabolism as a target for the anemia of chronic kidney disease?

Elena Canavesi, Carlo Alfieri, Serena Pelusi, Luca Valenti

Abstract
The anemia of chronic kidney disease and hemodialysis is characterized by chronic inflammation and release of cytokines, resulting in the upregulation of the iron hormone hepcidin, also increased by iron therapy and reduced glomerular filtration, with consequent reduction in iron absorption, recycling, and availability to the erythron. This response proves advantageous in the short-term to restrain iron availability to pathogens, but ultimately leads to severe anemia, and impairs the response to erythropoietin (Epo) and iron. Homozygosity for the common C282Y and H63D HFE polymorphisms influence iron metabolism by hampering hepcidin release by hepatocytes in response to increased iron stores, thereby resulting in inadequate inhibition of the activity of Ferroportin-1, inappropriately high iron absorption and recycling, and iron overload. However, in hemodialysis patients, carriage of HFE mutations may confer an adaptive benefit by decreasing hepcidin release in response to iron infusion and inflammation, thereby improving iron availability to erythropoiesis, anemia control, the response to Epo, and possibly survival. Therefore, anti-hepcidin therapies may improve anemia management in hemodialysis. However, HFE mutations directly favor hemoglobinization independently of hepcidin, and reduce macrophages activation in response to inflammation, whereas hepcidin might also play a beneficial anti-inflammatory and anti-microbial action during sepsis, so that direct inhibition of HFE-mediated regulation of iron metabolism may represent a valuable alternative therapeutic target. Genetic studies may offer a valuable tool to test these hypotheses and guide the research of new therapies.

© 2012 Baishideng. All rights reserved.

Key words: Chronic kidney disease; Hemodialysis; Iron; HFE protein; Iron overload

Peer reviewer: Daniel J Canter, MD, Assistant Professor, Emory University, Department of Urology, 1365 Clifton Road, NE, Atlanta, GA 30322, United States

Canavesi E, Alfieri C, Pelusi S, Valenti L. Hepcidin and HFE protein: Iron metabolism as a target for the anemia of chronic kidney disease? World J Nephrol 2012; 1(6): 166-176  Available from: URL: http://www.wjgnet.com/2220-6124/full/v1/i6/166.htm DOI: http://dx.doi.org/10.5527/wjn.v1.i6.166

INTRODUCTION
Anemia represents a common clinical problem in subjects with chronic kidney disease (CKD), and is associated with increased morbidity and mortality related to cardiovascular events, especially in patients undergoing chronic hemodialysis (CHD). The cause is multifactorial[1], but the deficit of the hypoxia-sensing hormone erythropoietin (Epo) that promotes the differentiation of erythroid progenitors into reticulocytes and red blood cells (RBCs) plays a major role. However, the persistence
of anemia despite Epo supplementation indicates a con-
comitant hyporesponsiveness of bone marrow, partly re-
lated to inadequate supply of substrates for hemoglobin
(Hb) synthesis, including folates, cyanocobalamin, and
iron. Furthermore, RBCs life-span is shortened in CKD,
and there is an increase trend of bleeding related to
uremia itself. Other causes of anemia include chronic
blood loss from gastroenteric system and blood trapping
in dialyzers, dietary restrictions, loss of taste for iron-
rich foods, secondary hyperparathyroidism determining
bone marrow fibrosis, and accumulation of inhibitors of
erthropoiesis related to uremia.

Another major contributor of the anemia of CKD
is the chronic inflammatory state. Chronic inflammation
and cytokines can worsen anemia by shortening erythro-
cyte life span, induce apoptosis of erythroid precursors,
and directly inhibit erythroid progenitor proliferation.
Inflammation and cytokines are independent predictors
of Epo hyporesponsiveness[3], and reduce the availability
of iron for hematopoiesis.

Routine monitoring of body iron stores and iron
supplementation are therefore essential components of
the management of patients with CKD, in particular of
those receiving CHD. Iron is an essential nutrient, and
besides its role in Hb synthesis, it plays a crucial role in
vital biochemical activities, as component of enzymes
and other molecular complexes. It nevertheless has to
be compartmentalized and maintained at a fixed level to
avoid any toxic effects, largely based on its ability to cata-
lize the generation of reactive oxygen intermediates[4].

IRON METABOLISM AND HFE
MUTATIONS

The human body contains approximately 3-5 g of iron, the
main part of which is employed within Hb in circulating
RBCs. Approximately 20%-30% of body iron is stored in
hepatocytes and in macropathies, to a large extent within
polymers of ferritin. A healthy individual absorbs daily 1-2
mg of iron from the diet, which is utilized to compensate
non-specific iron losses by desquamation of enterocytes
and epidermis and, in childhood age women, by period.
Erythropoiesis requires approximately 30 mg of iron per
day, mainly provided by the recycling of iron via macro-
phages, which ingest senescent RBCs and release iron,
which binds to circulating transferrin (TF).

Iron uptake in the duodenum/jejunum is mediated
by specific set of transport proteins and accessory en-
zymes that change the oxidation state of iron to facilitate
the transport process; the most important for systemic
regulation is named ferroportin-1 (Fp-1), which allows
the transport across basolateral membrane of enter-
cytes, macrophages and hepatocytes. It works as iron
exporter in association with the plasma ferroxidase ce-
ruloplasmin (Cp), even if enterocytes depend heavily on
the expression of an analogous transmembrane protein
called hephaestin. Ferric iron binds to plasmatic apo-
TF to form ferric iron-TF complex, which is the major
type of iron present in blood. The TF complex facilitates
the transport of iron to cells that express TF receptors
(TFR), including erythroid progenitors, and limits the
ability of iron to generate toxic radicals. Iron uptake in
the cells occurs primarily by the endocytic pathway, which
involves the interaction between TF and TFR. Not all
absorbed iron is utilized in metabolic processes, but it is
partly stored as reserve, both for use when iron levels are
low, and to prevent toxic effects of free iron in the cell,
and the major part of it is bound to ferritin. Under iron
overload conditions, ferritin levels increase dramatically,
particularly in the liver.

Systemic iron homeostasis is achieved by modulation
of the amount of iron absorbed. Intestinal iron absorp-
tion is regulated in response to iron need and availability
and erythropoiesis activity, (“storage” and “erythroid”
regulators), whereas “inflammatory” regulators commu-
nicate signals in response to infection or inflammation.
The amount of body storage modulates iron uptake: it is
well established that in iron-deficient conditions, iron
absorption is stimulated by two- to three-fold compared
to basal conditions, which are restored when iron storage
are reconstituted. The erythropoietic regulation partici-
pates when iron demand for Hb synthesis increases, inde-
dependently of body iron stores.

Hepcidin, a small antimicrobial peptide synthesized
by the liver[5], is the principal effector of the modulation
of iron metabolism, via its ability to bind Fp-1 on cellular
surface blocking its iron transport activity, and to increase
Fp-1 degradation[6]. In enterocytes, Fp-1 internalization
on the basolateral surface causes the retention of
absorbed iron with subsequent loss by desquamation, while
the same process in macrophages causes the failure to
release iron[7]. The final effect is the reduction of plasma
iron availability. Importantly, hepcidin is upregulated by
both increased iron stores and inflammation. On the oth-
er hand, hepcidin secretion is reduced in response to sig-
nals that cause an increase in iron release from cells, such
as iron deprivation, and stimulus to erythropoiesis. Thus,
hepcidin represents a common effector of the homeo-
static regulation of intercellular iron fluxes in response to
the iron stores, erythroid, and inflammatory regulators.

The transcription and secretion of hepcidin is regulat-
ed by a mechanism of iron sensing depending on a
complex of interacting proteins, including the hereditary
hemochromatosis (HH) protein called HFE, TFR-2, he-
mojuvin (HJV), bone morphogenetic protein 6 (BMP6),
matriptase-2 (TMPRSS6) and TF (Figure 1). Mutations in
HFE, TFR-2, HJV and the hepcidin gene (HAMP) are
responsible for HH, a common iron overload disorder
characterized by a deficit of hepcidin release or activ-
ity[7]. HFE mutations represent the most frequent cause
of HH in Caucasian adults[8], and the most common is a
single nucleotide substitution that causes the substitution
of a cysteine with a tyrosine at position 282 (C282Y),
which hampers HFE expression on the cell surface. Ho-
mozygosity for the C282Y mutation is observed very
frequently in Northern Europe (frequency 1/300-400),
whereas the prevalence decreases towards Southern Eu-
Canavesi E et al. Hepcidin and HFE in chronic kidney disease

A: Hereditary hemochromatosis protein (HFE) wild-type, healthy controls; B: HFE wild-type, end-stage renal disease (ESRD); C: HFE mutated, ESRD.

Bone morphogenetic protein 6 (BMP-6) binds to the co-receptor membrane hemojuvelin (m-HJV) and to the bone morphogenetic protein receptor (BMP-R) on the membrane of hepatocytes. This initiates phosphorylation of small mother against decapentaplegic (SMAD) proteins and the assembly of heteromeric complexes. After nuclear translocation, the heteromeric SMAD complexes stimulate transcription of the HAMP gene for hepcidin. Another pathway responsible for hepcidin expression involves interleukine (IL)-6/gp130 signaling via signal transducer and activator of transcription 3 (STAT3) nuclear translocation. Negative regulation of the BMP-HJV-hepcidin pathway is achieved through the proteolytic processing of membrane-HJV by matriptase-2 (TMPRSS6). Additional negative regulation of hepcidin transcription is provided by soluble-HJV, which acts as an antagonist of the BMP pathway by competing with m-HJV for BMP-6 binding. The hepcidin regulatory signaling pathway is also regulated by HFE, which interacts either with transferrin receptor 1 (TFR1) or transferrin receptor 2 (TFR2) according to serum transferrin saturation: in the presence of a high transferrin saturation HFE dissociates from TFR1 and binds TFR2 forming an iron sensing complex influencing hepcidin expression via SMAD/ERK signaling. Hepcidin secreted by the liver binds to the extracellular region of ferroportin 1 (Fp-1) on the basolateral membrane of duodenal enterocytes causing Fp-1 internalization, ubiquitination and degradation and consequently impaired intestinal iron absorption.

Figure 1 Role of the proteins and mediators involved in iron homeostasis and impact of hereditary hemochromatosis protein mutations in chronic kidney disease. A: Hereditary hemochromatosis protein (HFE) wild-type, healthy controls; B: HFE wild-type, end-stage renal disease (ESRD); C: HFE mutated, ESRD. Bone morphogenetic protein 6 (BMP-6) binds to the co-receptor membrane hemojuvelin (m-HJV) and to the bone morphogenetic protein receptor (BMP-R) on the membrane of hepatocytes. This initiates phosphorylation of small mother against decapentaplegic (SMAD) proteins and the assembly of heteromeric complexes. After nuclear translocation, the heteromeric SMAD complexes stimulate transcription of the HAMP gene for hepcidin. Another pathway responsible for hepcidin expression involves interleukine (IL)-6/gp130 signaling via signal transducer and activator of transcription 3 (STAT3) nuclear translocation. Negative regulation of the BMP-HJV-hepcidin pathway is achieved through the proteolytic processing of membrane-HJV by matriptase-2 (TMPRSS6). Additional negative regulation of hepcidin transcription is provided by soluble-HJV, which acts as an antagonist of the BMP pathway by competing with m-HJV for BMP-6 binding. The hepcidin regulatory signaling pathway is also regulated by HFE, which interacts either with transferrin receptor 1 (TFR1) or transferrin receptor 2 (TFR2) according to serum transferrin saturation: in the presence of a high transferrin saturation HFE dissociates from TFR1 and binds TFR2 forming an iron sensing complex influencing hepcidin expression via SMAD/ERK signaling. Hepcidin secreted by the liver binds to the extracellular region of ferroportin 1 (Fp-1) on the basolateral membrane of duodenal enterocytes causing Fp-1 internalization, ubiquitination and degradation and consequently impaired intestinal iron absorption. EPO: Erythropoietin; Epo-R: Erythropoietin receptor; s-HJV: Serum hemojuvelin; TSAT: Transferrin saturation.

A second and most frequent mutation is a substitution at position 63 of a histidine with an aspartate (H63D). This is a very common polymorphism in the general population, as 25%-30% of the population carries the H63D variant, but it has only a minor effect on HFE function. The penetrance of iron overload depends on age, gender, environmental factors, and on the role of the so-called modifier genes, e.g., the β-thalassemic trait that influences erythropoiesis. Variants of one among the various regulatory molecules involved in iron homeostasis can bring to iron overload (BMP6, HJV, SMAD4) or severe iron deficiency (matriptase-2 or TMPRSS6) by interfering with hepcidin secretion. In particular, germline mutations in TMPRSS6, which encodes the type
transmembrane serine protease matriptase-2, are associated to a rare form of iron deficiency anemia refractory to oral iron therapy (iron refractory iron deficiency anemia, IRIDA). The key features of this phenotype are congenital hypochromic, microcytic anemia, low mean corpuscular erythrocyte volume, low TF saturation (TS), abnormal iron absorption characterized by no hematological improvement following treatment with oral iron, abnormal iron utilization consisting of an incomplete response to parenteral iron and inappropriately high hepcidin levels. Moreover, recent genome-wide association studies show that very common polymorphisms in the TMPRSS6 gene represent, together with HFE mutations, a major determinant of the variation in iron status in the general population. The strongest TMPRSS6 association was observed with rs855791, a nonsynonymous coding SNP (resulting in an A736V substitution) in exon 17. In particular, the 736V allele was associated with lower serum iron concentration, lower TS, decreased Hb and reduced erythrocyte mean cell volume.

IRON METABOLISM AND ANEMIA IN CKD

CKD is associated with typical alterations in iron metabolism parameters, i.e., reduced TS and hyperferritinemia (Figure 1). Decreased TS reduces iron availability for erythropoiesis, and is supposed to be related to chronic inflammation, which decreases serum iron by inducing hepcidin, and/or blood losses. Hyperferritinemia is also frequently observed and, although in the most severe cases it may reflect excessive iron administration, in the majority of cases has also been ascribed to the state of malnutrition and chronic inflammation, which is associated with a greater risk of cardiovascular disease and with a worse outcome. Both inflammation and oxidative stress induce iron retention in monocytes/macrophages, and the transcription of ferritin. However, recent data highlight that ferritin levels reflect also body iron stores in CKD patients. Indeed, in this clinical setting, three types of situation related to iron-metabolism are observed: (1) Absolute iron deficiency, due to decreased total body iron stores. It is associated with serum ferritin levels <100 ng/mL, TS < 20%, and relatively low serum hepcidin. Due to very low iron stores, serum hepcidin is relatively low. This situation is common in CHD, due to low-grade but frequent blood losses (typically 1-3 g of iron/year); (2) Functional iron deficiency, associated with serum ferritin levels higher than 100 ng/mL. Iron stores are normal or even increased, but the Epo-stimulated bone marrow needs more iron from TF than the iron output from tissue stores, resulting in Epo resistance in 10%-20% of cases. Hepcidin can aggravate functional iron deficiency by decreasing the release of stored and macrophage iron and intestinal iron absorption, through Fp-1 downregulation; and (3) the most severe form, historically termed “reticuloendothelial blockage”, which usually occurs in the setting of acute or chronic inflammation/infection. It can be considered as an extreme form of functional iron deficiency and is associated with increased C reactive protein levels, TS < 20%, and normal to very high levels of ferritin. Iron stores are locked, partly because of very high hepcidin levels, and there is no release of iron to TF. Resistance to Epo therapy easily develops, especially if iron administration is limited by adherence to the “official” opinion-based upper cutoff. Thus, the pattern of anemia, hyposideremia and decreased TS, Epo resistance, and high ferritin is frequently observed in CHD patients.

Noteworthy, Epo administration reduces hepcidin levels and increases intestinal iron absorption in CHD patients, in order to facilitate iron delivery to the bone marrow when is needed for accelerated RBCs production, suggesting also that the beneficial effect of Epo may be partly mediated by normalization of hepcidin levels and of iron delivery. Indeed, Epo increases the need for iron, so that bone marrow requests strip iron off the circulating TF faster than TF can replenish it, resulting in a relative deficit of iron. Evidence now proves that adequate iron availability increases erythropoiesis and reduces Epo requirements. Thus, interpretation of iron status tests should incorporate consideration of the Hb level and Epo dose.

Accordingly, KDOQI guidelines suggest that iron supplementation should be administered during Epo treatment to maintain serum ferritin > 200 ng/mL and TS > 20%, or Chr > 29 pg/cell in CHD and serum ferritin > 100 ng/mL and TS > 20% in CKD or in patients in peritoneal dialysis. The upper limit of serum ferritin besides which there is no recommendation to routinely administer iron was set as 500 ng/mL. When ferritin level is greater than 500 ng/mL, decisions regarding iron administration should weigh Epo responsiveness, Hb and TS level, and the clinical status. The preferred route of iron administration in CHD patients is by intravenous (iv) infusion, since iron absorption from the gastrointestinal tract may be impaired, likely because of high hepcidin levels. On the other hand, in advanced CKD or peritoneal dialysis patients, iron can generally be administered orally.

IRON TOXICITY IN CKD: THE CARDIOVASCULAR AND INFECTIVE RISKS

Large doses of iron may exceed storage capacity leading to the release of unbound iron into the plasma, which can produce reactive oxygen species. Hyperferritinemia exceeding 800 ng/mL has indeed been associated with imminent death risk, and in particular cardiovascular death in CHD patients, even after adjustment for the confounding variables. In addition to traditional and population specific risk factors such as anemia, hyperhomocysteinemia, hyperphosphatemia and inflammation, iron has been implicated in the pathogenesis of the accelerated atherosclerosis in CHD, possibly affecting LDL.
oxidation and endothelial dysfunction[32-34] via increased oxidative stress[35]. Recent data confirm that in CHD patients hyperferritinemia reflects a relative increase in iron availability and a decrease in iron-specific anti-oxidant activity, is favored by HFE mutations, and represents a risk factor for advanced cardiovascular damage, as evaluated by the presence of plaques, both at carotid and femoral arteries and by the intima media thickness[36]. Furthermore, hepcidin and tumor necrosis factor (TNF) α levels have been correlated with vascular stiffness, another reliable predictor of cardiovascular events in CHD[37].

The underlying mechanism may involve iron trapping into endothelial cells, plaque macrophages, and vascular smooth muscle cells, with activation of the atherogenic process and progression of the plaque lesion. Indeed, a significantly higher iron content has been detected in atherosclerotic plaques than in healthy vascular tissue[38]. Iron mediated vascular damage in CHD seems to be associated with hepcidin upregulation, caused by chronic flogistic state, diminished hemofiltration by damaged kidneys, and also by chronic iron supplementation. This causes an accumulation of iron in macrophages, favoring oxidative stress and the induction of the release of pro-atherogenic cytokines, in particular macrophage chemotactic protein-1 (MCP-1)[39].

Moreover, iron overload has been associated with an increased incidence and severity of infections, related to the growth-promoting effect of iron on microbial pathogens and also to inhibition of phagocytosis[38], and of the anti-microbial molecule lactoferrin[39]. Infection risk in CKD patients depends not only on iron, but also on the severity of anemia[40], transfusions, and secondary splenic dysfunction. In patients with end stage renal disease, there are additional risk factors, such as the presence of catheters for dialysis (temporary or permanent), malnutrition related to dialytic losses of nutrients, and exposure to extracorporeal circulation. Although human data are not conclusive, it is still recommended that, as a precaution, i.v. iron is stopped in patients with ongoing bacteremia, as in vitro and in vivo studies demonstrated that administering iron during active infection may contribute to bacterial growth[41,42]. Nevertheless, correction of anemia is effective in reducing oxidative stress and, consequently, cardiovascular risk, decreasing morbidity and mortality and also producing regression of left ventricular hypertrophy in patients with CKD[43], so that a carefully balanced management of iron supplementation is needed in CKD/CHD patients.

**HFE MUTATIONS IN CKD**

Consistently with previous data[44], our group has shown that the two common C282Y and H63D mutations, present in about one third of subjects, are associated with increased baseline iron stores, a lower requirement of Epo and a trend to a lower requirement of iron supplementation in Italian CHD patients[45], suggesting that the alterations in iron metabolism associated with the presence of these genetic variants include not only increased iron stores, but also iron handling by macrophages after infection, and iron availability to the erythron. Importantly, iron stores were not lower, and the requirement of iron and Epo were not higher in patients carrying only the minor HFE: H63D mutation compared to those positive for the more severe variant C282Y or homozygous for the H63D mutation. It is possible that chronic inflammation and blood losses typical of CHD provide enough environmental pressure to magnify subtle alterations in cellular iron handling also in carriers of the milder and more common H63D mutation, which thus reach clinical significance, unlike to what it is observed in general population[46]. Therefore, HFE mutations possibly attenuate the effects of inflammation on iron metabolism, including reduced iron absorption, iron sequestration in macrophages, and erythroblast resistance to Epo, and protect against iron-related damage by favoring the delivery of intravenously administered iron to the erythron (Figures 1-3).

Our data even highlighted that the presence of HFE mutations was possibly associated with a reduced mortality. Indeed, in patients negative for HFE mutations, we observed a higher mortality due to sepsis, previously associated with a higher iron dosage[47,48], and due to cardiovascular disease, possibly linked to hypertension and thromboembolic events related to Epo[44][49] and oxidative stress related to iron[50]. Obviously, these data need confirmation in larger prospective studies and independent cohorts.

In the hypothesis that altered regulation of hepcidin release by iron stores might explain the apparent protective role of the HFE mutations on cardiovascular complications and on the response to Epo[51], we investigated whether the effect of HFE gene mutations on hepcidin-25, the active form of the hormone, could be involved in the pathophysiology of the alterations of iron metabolism and anemia. We confirmed increased levels of hepcidin-25 in CHD patients compared to healthy controls[52,53], and a preserved regulation of hepcidin-25 by iron stores and inflammation in this setting, as demonstrated by the very strong correlation with serum ferritin and CRP levels[52,54]. Interestingly, we also showed a negative correlation between hepcidin-25 and serum iron, and we found that in a subgroup of patients with stable disease, selected to avoid the confounding effect of the frequent presence of acute inflammation, blood losses, cancer, and recent variation in the dosage of therapy, hepcidin-25 negatively correlated with Hb levels. Since anemia and hyposideremia should rather decrease hepcidin levels, these findings suggest that hepcidin-25 plays a causal role in determining anemia by reducing iron availability to the erythron, thus implying that in CHD excessive iron administration may paradoxically hamper iron utilization for erythropoiesis by increasing hepcidin, and that the effect of inflammation on altered iron metabolism and erythropoiesis may be partly mediated by increased hepcidin levels. As a consequence, pharmacological downregulation of hepcidin may be beneficial for anemia control in CHD[55].
Thus, it seems that iron mediated vascular damage involves hepcidin upregulation, a mechanism that could be implicated also in the enhanced atherosclerotic process in CHD patients, in whom hepcidin levels are much higher than in general population. In *vitro* studies on patients with metabolic syndrome confirmed the enhanced release of MCP-1 in monocytes treated with iron[59], but only in the absence of *HFE* mutations that preclude intracellular iron accumulation[60]. Consistently, patients homozygous for the C282Y *HFE* mutation had lower MCP-1 levels than those affected by secondary iron overload and healthy control[61], whereas serum MCP-1 levels were significantly correlated with hepcidin-25, and were an independent predictor of the presence of carotid plaques, indicating an advanced atherosclerotic process, in patients with metabolic alterations[62].

**ANTI-HEPCIDIN DRUGS: THE FUTURE OF ANEMIA MANAGEMENT IN CHD?**

These results may have important clinical implications, as targeting the HFE/hepcidin/Fp-1 axis by pharmacological treatment may further improve the long-term outcomes of patients with CKD and in particular undergoing CHD, by reducing the amount of iron and Epo supplementation needed, improving iron utilization for erythropoiesis[63], and possibly ameliorating iron-induced inflammation. Several drugs are under development for this purpose, for example targeting the HFE/hepcidin/Fp-1 axis by pharmacological treatment may further improve the long-term outcomes of patients with metabolic syndrome confirmed the enhanced release of MCP-1 in monocytes treated with iron[59], but only in the absence of *HFE* mutations that preclude intracellular iron accumulation[60]. Consistently, patients homozygous for the C282Y *HFE* mutation had lower MCP-1 levels than those affected by secondary iron overload and healthy control[61], whereas serum MCP-1 levels were significantly correlated with hepcidin-25, and were an independent predictor of the presence of carotid plaques, indicating an advanced atherosclerotic process, in patients with metabolic alterations[62].

In a mouse model of anemia of chronic disease (ACD), neutralizing antibodies (Abs) directed against...
Inhibition of BMP-6 signaling

Mechanism of action

Direct inhibition of hepcidin

Ref. [65]

Inhibition of BMP-6 signaling

Antibody

Anti-BMP6 Abs

Ref. [66]

Inhibition of BMP type 1 receptor

Decoy receptor for BMP-6

Ref. [66]

Table 1 A list of anti-hepcidin therapies evaluated in experimental models or under pre-clinical development

| Drug               | Ref.     | Mechanism of action                                                                 | Experimental model                          | Effects                                           |
|--------------------|----------|-------------------------------------------------------------------------------------|---------------------------------------------|--------------------------------------------------|
| Anti-hepcidin Abs  | [65]     | Direct inhibition of hepcidin                                                       | Mouse model of ACD                         | Increased sensitivity to Epo                      |
| Anti BMP6 Abs      | [68]     | Inhibition of BMP-6 signaling                                                       | Mice                                        | Decrease hepcidin                                 |
| Dorosomorphin      | [66]     | Inhibition of BMP type 1 receptor                                                   | Cultured mouse pulmonary artery smooth muscle cells | Decrease hepcidin                                 |
| Soluble HJV        | [55]     | Decoy receptor for BMP-6 (competition of membrane HJV and soluble HJV for BMP binding) | Hepatoma-derived HepG2 cells, Mice          | Decrease hepcidin                                 |
| Heparins           | [69]     | BMP-6 sequestration and consequent inhibition of BMP-6 signaling                    | Hepatoma-derived HepG2 cells, Mice          | Increase serum iron and transferrin saturation   |
| Epo                | [67]     | Increase HIF signaling, direct effect?                                              | Mouse hepatocytes, Hepatoma-derived HepG2 cells, Mice | Increase serum iron and transferrin saturation   |
| Spiegelmers        | [71]     | Bind and neutralise hepcidin biological activity                                   | Mouse macrophages, Mice                    | Inhibition of hepcidin-induced ferroportin degradation |
| Anticalins         | [72]     | Encapsulate and neutralise hepcidin biological activity                             | Cell system, Mice, Monkeys                 | Inhibition of hepcidin-induced hypoferremia      |

Abs: Antibodies; ACD: Anemia of chronic diseases; HJV: Hemojuvelin.

hepcidin restored the reticulocyte response and normal Hb levels in combination with Epo, whereas Epo alone, and Epo plus iv iron, were ineffective. Furthermore, overexpression of hepcidin in mice was sufficient to hamper the erythropoietic response to Epo. These preliminary preclinical data suggest that anti-hepcidin therapies could restore susceptibility in patients with Epo resistance or reduce the dose of Epo and iron required to achieve anemia control, thereby minimizing side effects.

A different approach to control hepcidin activity is represented by the modulation of hepcidin expression by targeting bone morphogenetic proteins (BMPs) activity. Administration of soluble forms of HJV (sHJV) inhibits BMP signaling and hepcidin expression, likely by binding to BMP6 and preventing the interaction with BMP receptors,[88], and could be exploited as a treatment for ACD.[88]. It was also shown that anti-BMP6 Abs were similarly effective.[88]. A promising development was provided by the recognition of the inhibitory activity of heparins on hepcidin release. Heparan sulfate proteoglycans (HSPGs) are expressed on the surface of various cell types and in the extracellular matrix, and modulate BMP osteogenic activity by binding BMPs, BMP antagonist, and BMP receptors. Heparin, a proteoglycan analog to HSPGs, strongly down-modulated hepcidin release in vivo and in vitro, resulting in increased serum iron and decreased splenic iron levels.[88]. The effect seemed to depend on the sequestration of BMP6, thereby preventing the interaction with HJV and the induction of hepcidin transcription. Importantly, heparin not only hampered BMP6 dependent induction of SMAD phosphorylation and hepcidin transcription, but could also prevent the IL-6 and STAT3 dependent activation of hepcidin promoter, suggesting that it may overcome the effect of inflammation on hepcidin release also in patients with ACD or CKD. Due to the dose-dependent anticoagulant effects and the need for therapeutic monitoring, it is unlikely that unfractioned heparin could ever be implemented as a therapy for the anemia of chronic disease or CHD anemia in patients without thrombophilic conditions. However, it is conceivable that heparin could be modified to improve the anti-hepcidin while decreasing anticoagulant activity.[88]. Another possibility consists in the downstream inhibition of BMP receptors. Dorosomorphin has been identified through a large scale in vivo screening approach as a selective inhibitor of BMP signaling through the antagonism of type 1 receptors activity.[86]. Interestingly, this small molecule compound was able to profoundly reduce basal hepcidin levels and increase serum iron in mice. However, due to the many roles of BMP signaling in the regulation of cell differentiation and homeostasis, it is likely that dorosomorphin, that for example effectively inhibits osteogenesis in vivo, would have unacceptable side effects in humans.

It should not also be forgotten that large doses of Epo could reduce hepcidin levels, even if the effect seems to require the effective induction of erythropoietic activity in vivo, and is therefore subjected to clinical resistance, and to side effects. In conclusion, the association of anti-hepcidin Abs, or possibly anti-BMP6 Abs or anti-inflammatory/anti-hepcidin heparins, to Epo represents the most promising approach for the treatment of the anemia of CHD and chronic diseases.
Novel approaches include also the exploitation of small-engineered molecules that directly inhibit hepcidin. These include the spiegelmer NOX-H94, that is a RNA molecule with secondary structures complementary to that of hepcidin, demonstrating inhibitory activity in *in vitro* and *in vivo* in mouse models with a consequent increase in iron levels, and PRS-080, a pegylated form of an anti-calin, which binds and inactivates hepcidin.

In recent years, it became possible to act also on the efficiency of dialysis. The use of new dialysis techniques and more efficient filters, allows the removal of larger quantities and types of toxins. Among all, the haemodiafiltration technique (HDF) is used to combine the advantages of the removal of low molecular weight solutes by diffusive transport (the concentration gradient between dialysate and plasma) with the advantages of removing substances to medium-high molecular weight by convective transport. Many studies have shown that, compared to bicarbonate dialysis, HDF allows greater removal of solutes with low-medium molecular weight, including some fraction of complement (C3a, C5a) and proinflammatory cytokines (e.g., TNF-α), substances related with an inflammatory basic status, and possibly also of hepcidin, even if available data are not conclusive.

**A NOTE OF CAUTION**

As *HFE* has been demonstrated to be directly involved in the maturation of erythroid progenitors, inflammation and atherogenesis, it should be noted that the advantageous effect of the presence of *HFE* mutations on erythropoiesis in CHD patients may not be completely dependent on the only relatively decreased hepcidin levels in patients carrying *HFE* mutations. Therefore, even if the degree of hepcidin activity suppression achievable in vivo would likely play a major role in determining iron availability to erythropoiesis, it is possible that anti-hepcidin therapies would result in a lesser improvement in anemia control than that conferred by the presence of protective *HFE* genotypes. These remarks are reinforced by the recent demonstration that hepcidin, by modulating iron metabolism and STAT3 signaling in leukocytes, may also exert an anti-inflammatory activity in models of acute shock, possibly resulting in an improved survival. Therefore, it is possible that while it negatively affects anemia control, at the same time hepcidin improves mortality during severe infections, which are commonly observed in CHD patients. The picture is further complicated by the possibility that increased cytokine release related to low basal hepcidin levels may offer protection against the development of infections.

Anyway, the finding that the serine protease TMPRSS6 regulates hepcidin levels has highlighted novel potential applications of hepcidin-targeted therapy for the treatment of iron disorders. For example, inhibition of the protease function of TMPRSS6 might be beneficial for disorders in which hepcidin is inappropriately low such as HH and iron loading anemias. Similarly, treatment with agonists or with the endogenous substrate of TMPRSS6 might be employed in the anemia of chronic disease, such as CKD, in which hepcidin levels are high. However, because of the anti-inflammatory action of hepcidin, a careful approach is needed when considering to intervene on the hepcidin pathway. Meanwhile, the evaluation of the effect of the common TMPRSS6 polymorphisms, which influence hepcidin release without affecting HFE function, on the outcome of CHD patients may provide some answers to these questions and a possible model for the clinical effect of anti-hepcidin therapies.

A better comprehension of the mechanisms linking *HFE* mutations with altered protein function both related to iron sensing/hepcidin induction and to the direct control of cellular iron intake would also be needed to design new therapeutic approaches aimed specifically at directly inhibiting this molecule. Furthermore, the possible development of side effects, such as the promotion of carcinogenesis related to chronic exposure to high TS levels, which would result from the inhibition of hepcidin, should be weighted against the potential benefits.

**CONCLUSION**

The anemia of CKD and CHD is characterized by chronic inflammation and release of cytokines, resulting in increased hepcidin with consequent reduction in iron absorption, recycling, and availability to the erythron. This response proves advantageous in the short-term to restrain iron availability to pathogens during infections, but in the case of chronicization, it leads to severe anemia, and may impair the response to Epo and iron therapy. Furthermore, as hepcidin is freely filtered by the glomerulus, CKD itself is a contributing factor to increased hepcidin levels.

The common polymorphisms C282Y e H63D in the HFE gene of hemochromatosis represent a major determinant of iron metabolism: these genetic factors act by hampering hepcidin induction in hepatocytes in response to increased iron stores, thereby resulting in reduced serum hepcidin-25 and inadequate inhibition of the activity of the iron exporter Fp-1, inappropriately high duodenal iron absorption, iron recycling from erythropagocytosis, and increased serum iron. However, in CHD patients *HFE* mutations may confer an adaptive benefit by decreasing hepcidin release in response to iron and inflammation, thereby improving iron availability to erythropoiesis, anemia control, and the response to Epo and iron. The subtle effect of the C282Y and H63D mutations is likely magnified in CHD patients by the environmental pressure determined by chronic inflammation, and exposure to high amounts of iron and Epo. Although data must be confirmed in large prospective studies, this favorable shift in iron metabolism balance possibly results in reduced mortality, in particular because of cardiovascular and infective diseases. Evidence is also
accumulating that HFE mutations directly favor erythroblast maturation and hemoglobinization independently of hepcidin, and reduce activation of macrophages in response to inflammation. These data suggest that anti-hepcidin therapies such as anti-hepcidin or anti-BMP6 Abs may improve anemia management in CHD patients concomitantly sparing the doses and side-effects of Epo and iron and resulting in better quality-of-life and survival. However, as the beneficial effect of HFE mutations on iron metabolism in CHD does not seem to be fully explained by lower hepcidin levels, and hepcidin might also play a beneficial anti-inflammatory and anti-microbial action during sepsis, direct inhibition of HFE-mediated regulation of iron metabolism may represent a valuable alternative therapeutic target. Genetic studies may offer a valuable tool to test these hypotheses and guide the research of new therapies.

REFERENCES

1. Lankhorst CE, Wish JB. Anemia in renal disease: diagnosis and management. Blood Rev 2010; 24: 39-47
2. Gunnell J, Yeun JY, Depner TA, Kaysen GA. Acute-phase responses predict erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 1999; 33: 63-72
3. Papanikolaou G, Pantopoulos K. Iron metabolism and toxicity. Toxicol Appl Pharmacol 2005; 202: 199-211
4. Andrews NC. Forging a field: the golden age of iron biology. Blood 2008; 112: 219-230
5. Pigeon C, Illyin G, Courseulaud B, Leroyer P, Turlin B, Brisot P, Lœrlâl O. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem 2001; 276: 7811-7819
6. Nemeth E, Tuttle MS, Powellson J, Vaughn MB, Donovan A, Ward DM, Ganz T, Kaplan J. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004; 306: 2090-2093
7. Pietrangelo A. Hemochromatosis: an endocrine liver disease. Hepatology 2007; 46: 1291-1301
8. Camaschella C. Understanding iron homeostasis through genetic analysis of hemochromatosis and related disorders. Blood 2005; 106: 3700-3717
9. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, Dormishian F, Domingo R, Ellis MC, Fullan A, Feder JN. Human beta-thalassaemia trait. Br J Haematol 2000; 111: 908-914
10. Valenti L, Canavesi E, Galmozzi E, Dongiovanni P, Rametta R, Bamonti F, Novembrino C, Fargion S. Relationship between TNF-alpha and iron metabolism in differentiating human monocyctic THP-1 cells. Br J Haematol 2000; 110: 978-984
11. Torti FM, Torti SV. Regulation of ferritin genes and protein. Blood 2002; 99: 3505-3516
12. Valenti L, Valenti G, Como G, Burell L, Santorso G, Dongiovanni P, Rametta R, Bamonti F, Novembrino C, Fargion S, Meza PG, Fargion S. HFE gene mutations and oxidative stress influence serum ferritin, associated with vascular damage, in hemodialysis patients. Am J Nephrol 2007; 27: 101-107
13. Kalantar-Zadeh K, Rodriguez RA, Humphreys MH. Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients. Nephrol Dial Transplant 2004; 19: 141-149
14. Finberg KE. Iron-refractory iron deficiency anemia. Semin Hematol 2009; 46: 378-386
15. Benyamin B, Ferreira MA, Willemsen G, Gordon S, Middelberg RP, McEvoy BP, Hottenga J, Henders AK, Campbell MJ, Wallace L, Frazer IH, Heath AC, de Geus EJ, Nyholt DR, Visscher PM, Penninx BW, Boomsma DI, Martin NG, Montgomery GW, Whitfield JB. Common variants in TMRPRES are associated with iron status and erythrocyte volume. Nat Genet 2009; 41: 1173-1175
16. Kalantar-Zadeh K, McAllister CJ, Lehn RS, Liu E, Koppel JD. A low serum iron level is a predictor of poor outcome in hemodialysis patients. Am J Kidney Dis 2004; 43: 671-684
17. Kalantar-Zadeh K, Regidor DL, McAllister CJ, Michael B, Warnock DG. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 2005; 16: 3070-3080
18. Scaccabarozzi A, Arosio P, Weiss G, Valenti L, Dongiovanni P, Fracanzani AL, Mattioli M, Levi S, Fiorelli G, Fargion S. Relationship between TNF-alpha and iron metabolism in differentiating human monocyctic THP-1 cells. Br J Haematol 2000; 110: 978-984
19. Torti FM, Torti SV. Regulation of ferritin genes and protein. Blood 2002; 99: 3505-3516
20. Valenti L, Valenti G, Como G, Burell L, Santorso G, Dongiovanni P, Rametta R, Bamonti F, Novembrino C, Fargion S, Meza PG, Fargion S. HFE gene mutations and oxidative stress influence serum ferritin, associated with vascular damage, in hemodialysis patients. Am J Nephrol 2007; 27: 101-107
21. Eschbach JW, Cook JD, Finch CA. Iron absorption in chronic renal disease. Clin Sci 1970; 38: 191-196
22. Donnelly SM, Posen GA, Ali MA. Oral iron absorption in hemodialysis patients treated with erythropoietin. Clin Nephrol 1991; 14: 271-276
23. Kooistra MP, Marx J. The absorption of iron is disturbed in recombinant human erythropoietin-treated peritoneal dialysis patients. Nephrol Dial Transplant 1998; 13: 2578-2582
24. Michiels R, Gery R, Sela S, Shurtz-Swirski R, Grinberg N, Smitskovski T, Shasha SM, Kristal B. Carbonyl stress induced by intravenous iron during haemodialysis. Nephrol Dial Transplant 2003; 18: 924-930
25. Kalantar-Zadeh K, Don BR, Rodriguez RA, Humphreys MH. Serum ferritin is a marker of morbidity and mortality in hemodialysis patients. Am J Kidney Dis 2001; 37: 564-572
26. Feldman HI, Santanna J, Gao W, Forst H, Franklin E, Jofle M, Marcus S, Faich G. Iron administration and clinical outcomes in hemodialysis patients. J Am Soc Nephrol 2002; 13: 734-744
27. Brugnara C. Reticulocyte cellular indices: a new approach in the diagnosis of anemias and monitoring of erythropoietic function. Crit Rev Clin Lab Sci 2000; 37: 93-130
28. Besarab A, Amin N, Ahsan M, Vogel SE, Zazzuwa G, Frinak S, Zaza J, Anandan JV, Gupta A. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 2000; 11: 530-538
29. Canavesi E, Galmozzi E, Dongiovanni P, Rametta R, Bamonti F, Novembrino C, Fargion S. HFE gene mutations and oxidative stress influence serum ferritin, associated with vascular damage, in hemodialysis patients. Am J Nephrol 2007; 27: 101-107
30. Canavesi E et al. Hepcidin and HFE in chronic kidney disease.
ity for a hereditary hemochromatosis gene is associated with cardiovascular death in women. Circulation 1999; 100: 1268-1273

Zalewski LR, Chow B, Lavori PW, Howes PS, Bell MR, DiTommaso MA, Carnegie NM, Bech JB, Amidi M, Muluk S. The iron (Fe) and atherosclerosis study (FeAST): a pilot study of reduction of body iron stores in atherosclerotic peripheral vascular disease. Am Heart J 2000; 139: 337-345

Wolf B, Volzke H, Lüdemann J, Robinson D, Vogelgesang D, Staudt A, Kessler C, Dahm JB, John U, Felix SB. Association between high serum ferritin levels and carotid atherosclerosis in the study of health in Pomerania (SHIP). Stroke 2004; 35: 453-457

Kuragano T, Itoh K, Shimonaka Y, Kida A, Furuta M, Kitamura R, Yahiyo N, Nanami M, Otaki Y, Hasuike Y, Nonoguchi H, Nakanishi T. Hepcidin as well as TNF-a are significant predictors of arterial stiffness in patients on maintenance hemodialysis. Nephrol Dial Transplant 2011; 26: 2663-2673

Stadler N, Lindner RA, Davies MJ. Direct detection and quantification of transition metal ions in human atherosclerotic plaques: evidence for the presence of elevated levels of iron and copper. Arterioscler Thromb Vasc Biol 2004; 24: 949-954

Valenti L, Dongiovanni P, Motta BM, Swinkels DW, Bonara P, Rametta R, Burdick L, Frugoni C, Fracanzani AL, Fargion S. Serum hepcidin and macrophage iron correlate with MCP-1 release and vascular damage in patients with metabolic syndrome alterations. Arterioscler Thromb Vasc Biol 2011; 31: 683-690

Cieri E. Does iron cause bacterial infections in patients with end stage renal disease? ANNA J 1999; 26: 591-596

Ellison RT, Giehl TJ. Killing of gram-negative bacteria by lactoferrin and lysozyme. J Clin Invest 1991; 88: 1080-1091

Hershko C, Thomas JY, Nolan GA, Sadow ME. Hepcidin and HFE in chronic kidney disease. Clin Infect Dis 2007; 45: 1381-1387

Valent L, Girelli D, Valenti GF, Castagna A, Como G,Campostrini N, Rametta R, Dongiovanni P, Messa P, Fargion S. HFE mutations modulate the effect of iron on serum hepcidin-25 in chronic hemodialysis patients. Clin J Am Soc Nephrol 2009; 4: 1331-1337

Tomosugi N, Kawabata H, Wakatabe R, Higuchi M, Yamaya H, Umehara H, Ishikawa I. Detection of serum hepcidin in renal failure and inflammation by using ProteinChip System. Blood 2006; 108: 1381-1387

Kemna EH, Tjalsma H, Willems LW, Swinkels DW. Hepcidin: iron discovery to differential diagnosis. Haematologica 2008; 93: 90-97

Kato A, Tsuji T, Luo J, Sako Y, Yasuda H, Ishihda A. Association of prohepcidin and hepcidin-25 with erythropoietin response and ferritin in hemodialysis patients. Am J Nephrol 2008; 28: 115-121

Babitt JL, Huang FW, Xia Y, Sidis Y, Andrews NC, Lin HY. Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. J Clin Invest 2007; 117: 1933-1939

Ramos P, Guy E, Chen N, Poonch CC, Gardenghi S, Casu C, Follenzi A, Van Rooijen N, Grady RW, de Sousa M, Rivella S. Enhanced erythropoiesis in Hfe-KO mice indicates a role for Hfe in the modulation of erythroid iron homeostasis. Blood 2011; 117: 1379-1389

Forejtniková H, Viellevoye M, Zermati Y, Lambert M, Peligrino RM, Guihard S, Gaudry M, Casamchella C, Lacombe C, Roetto A, Mayeux P, Verdier F. Transferin receptor 2 is a component of the erythropoietin receptor complex and is required for efficient erythropoiesis. Blood 2010; 116: 5357-5367

Valenti L, Swinkels DW, Burdick L, Dongiovanni P, Tjalsma H, Motta BM, Bertelli C, Fatta E, Bignamini D, Rametta R, Fargion S, Fracanzani AL. Serum ferritin levels are associated with vascular damage in patients with nonalcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2011; 21: 568-575

Sullivan JL. Macrophage iron, hepcidin, and atherosclerotic plaque stability. Exp Biol Med (Maywood) 2007; 232: 1014-1020

Yuan XM, Li W, Baird SK, Carlsson M, Melefors O. Secretion of ferritin by iron-laden macrophages and influence of lipoproretins. Free Radic Res 2004; 38: 1133-1142

Kramil P, Klein RL, Huang Y, Nareika A, Lopes-Virella MF. Iron loading increases cholesterol accumulation and macrophage scavenger receptor I expression in THP-1 mononuclear phagocytes. Metabolism 2005; 54: 453-459

Garuti C, Tian Y, Montosi G, Sabelli M, Corradini E, Graf R, Ventura P, Veggetti A, Clavien PA, Pietrangelo A. Hepcidin expression does not rescue the iron-poor phenotype of Kupffer cells in Hfe-null mice after liver transplantation. Gastroenterology 2010; 139: 315-322.e1

Lawless MW, White M, Mankin AK, O'Dwyer MJ, Norris S. Elevated MCP-1 serum levels are associated with the H63D mutation and not the C282Y mutation in hereditary hemochromatosis. Tissue Antigens 2007; 70: 294-300

Babitt JL, Lin HY. Molecular mechanisms of hepcidin regulation: implications for the anemia of CKD. Am J Kidney Dis 2010; 55: 726-741

Sasu BJ, Cooke KS, Arvedson TL, Plewa C, Ellison AR, Sheng J, Winters A, Juan T, Li H, Begley CG, Molineux G. Antilepidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced iron therapy. Clin Infect Dis 2004; 38: 1090-1094

Miyashita K, Tojo A, Kimura K, Goto A, Omata M, Nishiyama K, Fujita T. Blood pressure response to erythropoietin injection in hemodialysis and predialysis patients. Hypertens Res 2004; 27: 79-84

Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoetin: a meta-analysis. Lancet 2007; 369: 381-388

Valenti L, Girelli D, Valenti GF, Castagna A, Como G, Campostrini N, Rametta R, Dongiovanni P, Messa P, Fargion S. HFE mutations modulate the effect of iron on serum hepcidin-25 in chronic hemodialysis patients. Clin J Am Soc Nephrol 2009; 4: 1331-1337

December 6, 2012 | Volume 1 | Issue 6 | WJN | www.wjgnet.com
Canavesi E et al. Hepcidin and HFE in chronic kidney disease

anemia. Blood 2010; 115: 3616-3624

Yu PB, Hong CC, Sachidanandan C, Babitt JL, Deng DY, Hoyng SA, Lin HY, Blich KD, Peterson RT. Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat Chem Biol 2008; 4: 33-41

Pinto JP, Ribeiro S, Pontes H, Thowfeequ S, Tosh D, Carvalho F, Porto G. Erythropoietin mediates hepcidin expression in hepatocytes through EPOR signaling and regulation of C/EBPalpha. Blood 2008; 111: 5727-5733

Andriopoulos B, Corradini E, Xia Y, Faasse SA, Chen S, Grgurevic L, Knutson MD, Pietrangelo A, Vukicovic S, Lin HY, Babitt JL. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat Genet 2009; 41: 482-487

Poli M, Girelli D, Campostrini N, Maccarinelli F, Finazzi D, Luscieti S, Nai A, Arosio P. Heparin: a potent inhibitor of hepcidin expression in vitro and in vivo. Blood 2011; 117: 997-1004

Ceccarelli M, Bani D, Cinci L, Nistri S, Uliva C, Ragazzo E, Vannacci A, Manoni M, Gori AM, Abbate R, Gensini GF, Masini E. Anti-inflammatory effects of low molecular weight heparin derivative in a rat model of carrageenan-induced pleurisy. J Cell Mol Med 2009; 13: 2704-2712

van Eijk L, Swinkels DW, Aaron J, Schoebel F, Fliegert F, Summo L, Stéphanie V, Laarakkers C, Riecke K, Pkkers P. Randomized double blind placebo controlled PK/PD study on the effects of a single intravenous dose of the anti-hepcidin spiegelmer Nox-H94 on serum iron during experimental human endotoxemia. 54th meeting American Society of Hematology, 2012. Available from: URL: https://ash.confex.com/ash/2012/webprogram/Paper50672.html

Hohlbbaum AM, Trentman S, Gille H, Allersdorfer A, Siham Belaiba R, Huelsmeyer M, Christian J, Sandal T, Matschiner G, Jensen K, Skerra A, Audoly LP. Discovery and preclinical characterization of a novel hepcidin antagonist with tunable PK/PD properties for the treatment of anemia in different patient populations. 53rd meeting American Society of Hematology, 2011. Available from: URL: https://ash.confex.com/ash/2011/webprogram/Paper40699.html

Ding F, Ahrenholz P, Winkler RE, Ramlow W, Tiess M, Michelsen A, Fatow W. Online hemodiafiltration versus acetate-free biofiltration: a prospective crossover study. Artif Organs 2002; 26: 169-180

Bonforte G, Grillo P, Zerbi S, Surian M. Improvement of anemia in hemodialysis patients treated by hemodiafiltration with high-volume on-line-prepared substitution fluid. Blood Purif 2002; 20: 357-363

Camposstri N, Castagna A, Zaninotto F, Bedogna V, Teshitore N, Poli A, Martinelli N, Lupo A, Olivieri O, Girelli D. Evaluation of hepcidin isoforms in hemodialysis patients by a proteomic approach based on SELDI-TOF MS. J Biomed Biotechnol 2010; 2010: 329646

Pagani A, Nai A, Corna G, Bosurgi L, Rovere-Querini P, Camaschella C, Silvestri L. Low hepcidin accounts for the proinflammatory status associated with iron deficiency. Blood 2011; 118: 736-746

De Domenico I, Zhang TY, Koenig CL, Branch RW, London N, Lo E, Daynes RA, Kushner JP, Li D, Ward DM, Kaplan J. Heparin mediates transcriptional changes that modulate acute cytokine-induced inflammatory responses in mice. J Clin Invest 2010; 120: 2395-2405

Zacharski LR, Chow BK, Howes PS, Shamaeva G, Baron JA, Dalman RL, Malenko DJ, Ozaki CK, Lavori PW. Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial. J Natl Cancer Inst 2008; 100: 996-1002

Dongiovanni P, Fracanzani AL, Cairo G, Megazzini CP, Gatti S, Rametta R, Fargion S, Valenti L. Iron-dependent regulation of MDM2 influences p53 activity and hepatic carcinogenesis. Am J Pathol 2010; 176: 1006-1017

Fargion S, Valenti L, Fracanzani AL. Hemochromatosis gene (HFE) mutations and cancer risk: expanding the clinical manifestations of hereditary iron overload. Hepatology 2010; 51: 1119-1121